# A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

> **NCT00784550** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 342 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium Bromide
- **DRUG:** Fluticasone Propionate/Salmeterol

## Key facts

- **NCT ID:** NCT00784550
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784550, "A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00784550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*